Seeking Alpha·Sep 14, 2026
CG Oncology, Inc. (CGON) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptCG Oncology, Inc. (CGON) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
CG Oncology is a pre-commercial biotechnology company developing cretostimogene grenadenorepvec for non-muscle invasive bladder cancer, with a robust balance sheet of $1.0B equity but a rapidly shrinking cash position of $19.6M as of 2026Q2. The company's clin...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue is negligible at $1.2M in 2026Q2 with a negative gross margin of -2.4%, while R&D expenses of $54.7M drive operating losses of -$86.4M, reflecting a pre-commercial stage with escalating clinical costs.
CG Oncology initiated a rolling BLA submission for cretostimogene in high-risk BCG-unresponsive NMIBC, with full completion targeted for 2026, paving the way for potential FDA approval and launch by 2027.
The company's investment thesis centers on a pivotal Phase 3 trial for cretostimogene, with positive results significantly de-risking the stock and driving investor interest.
Bull Case scenarios project rapid adoption of cretostimogene, with potential FY2028 revenue reaching ~$700 million, significantly outperforming base and bear cases.
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 7, 2026 | -$0.90-35.5% vs -$0.66 | $1M+220.7% vs $360,805 |
Q3 2026 Aug 6, 2026 | -$0.90-35.5% vs -$0.66 | $1M+220.7% vs $360,805 |
Q2 2026 May 8, 2026 | -$0.71-22.4% vs -$0.58 | $1M+139.1% vs $453,034 |
Q1 2026 Feb 27, 2026 | -$0.51+16.4% vs -$0.61 | $2M+412.9% vs $450,538 |
CG Oncology, Inc. (CGON) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Jupiter Topco LLC purchased a new stake in shares of CG Oncology, Inc. (NASDAQ: CGON) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 23,000 shares of the company's stock, valued at approximately $1,634,000. Several other large investors have also recently
Bond yields have the entire stock market on edge. The last thing most investors are thinking about is short squeezes, which means maybe they should be something contrarian trades have on their radar.
DALLAS, Sept. 02, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentations at the Cantor Fitzgerald and Morgan Stanley Global Healthcare Conferences in New York City this month. The details of the upcoming events are as follows:
Benchmark CGON against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for CG Oncology Inc. (CGON)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $77.74 | $6.86B | -37.38 | 254.7% | -3985.02% | -21.67% | — | |
| $68.68 | $477.25M | 9.59 | 11.92% | 13.11% | 9.3% | — | |
| $37.29 | $7.7B | -13.46 | — | -7585.86% | -69.59% | — | |
| $58.11 | $8.9B | 20.98 | 87.32% | 55.22% | 72.3% | — | |
| $17.47 | $1.07B | -9.55 | -5.55% | -321.81% | -10.79% | — | |
| $26.87 | $3.38B | -8.17 | -4.26% | -386.32% | -87.98% | — |
CG Oncology Inc. (CGON) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
CG Oncology Inc. (CGON) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jun 8, 2026·SEC
May 26, 2026·SEC
Get notified when CGON posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CG Oncology Inc. (CGON) stock FAQ — growth, dividends, profitability & financials explained
CG Oncology Inc. (CGON) reported $6.2M in revenue for fiscal year 2025. This represents a 40% decrease from $10.4M in 2021.
CG Oncology Inc. (CGON) grew revenue by 254.7% over the past year. This is strong growth.
CG Oncology Inc. (CGON) reported a net loss of $224.4M for fiscal year 2025.
CG Oncology Inc. (CGON) has a return on equity (ROE) of -21.7%. Negative ROE indicates the company is unprofitable.
CG Oncology Inc. (CGON) had negative free cash flow of $179.3M in fiscal year 2025, likely due to heavy capital investments.
